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1. Introduction 
The problem of finding effective chemotherapies for advanced cancer remains largely unsolved. 
We review here the role of a specific class of central metabolic dehydrogenases whose 
regulatory properties are remodeled significantly in cancer cells. These remodeled properties 
may provide an attractive set of targets for the development of new chemotherapeutic drugs. 
The design features of the first agents to be developed attacking these new targets [1,2] may 
illustrate ways to exploit this potentially valuable therapeutic opportunity. 
2. The central role of the pyruvate dehydrogenase (PDH) and alpha-
ketoglutarate (KDGH) complexes in cell metabolism 
The evolution of the high-energy, oxygen-dependent metabolism of eukaryotes [4,5] has 
produced mitochondrial metabolic pathways whose control is centrally focused on a series 
of dehydrogenases. Two of these pivotal dehydrogenases, the pyruvate dehydrogenase 
(PDH) and alpha-ketoglutarate or 2-oxoglutarate (KDGH) complex will be our central focus 
here. These dehydrogenases control the entry of carbon into the TCA cycle from two major 
sources, carbohydrate and gluconeogenic amino acids (pyruvate; PDH) and glutamine 
(KGDH), the most abundant serum amino acid and a central carbon source for normal and 
pathological tissues (Figure 1). The TCA cycle, in turn, is almost exclusively responsible for 
the capture of reducing potential from nutrients for the purpose of driving the oxygen-
dependent mitochondrial electron transport system for ATP production [6]. 
In the solid, three dimensional structure of animal bodies the availability of nutrients and 
molecular oxygen is locally contingent and dynamically variable. Thus, continuous real-time 
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control of PDH and KGDH activities is essential to proper function. Moreover, in various 
pathological contexts these regulatory processes are substantially altered in ways that are 
essential to that pathology and this may reflect targets for therapeutic intervention (see 
sections 5 and 8 below for detailed references). 
 
Figure 1. The pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase (KGDH) 
complexes govern the entry of carbohydrate- and glutamine-derived carbon, respectively, into the TCA 
cycle. Glucose and glutamine are two major carbon sources feeding many mammalian cells, including 
tumor cells. These molecules are metabolized to support ATP generation, through cytosolic glycolysis 
and oxygen-dependent mitochondrial metabolism in which most reducing potential is  derived from 
the TCA cycle. As well, both carbon and reducing potential from glucose and glutamine are delivered 
to anabolic, biosynthetic functions. Among these are provision of citrate and NADPH for lipid 
biosynthesis as illustrated and delivery of carbon skeletons from glycolysis and the TCA cycle for amino 
acid biosynthesis (not illustrated). The entry of glucose derived carbon (either from dietary glucose or 
from amino acids used for gluconeogenesis) is controlled by the PDH complex and the entry of 
glutamine derived carbon is controlled by the KGCH complex. Figure redrawn from several sources, 
including [3]. 
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PDH decarboxylates pyruvate, releasing carbon dioxide, capturing reducing potential and 
transferring the two-carbon acyl unit (acetate) to Co-enzyme A (CoA) (Figure 2). 
Structurally homologous KGDH catalyzes the analogous reaction, decarboxylating alpha-
ketoglutarate and generating succinyl-CoA. Each of these reactions is highly exergonic and 
also generates rapidly dispersed or consumed products (carbon dioxide and acyl-CoA). 
Thus, the initial decarboxylation reaction in each case is effectively irreversible, reflecting a 
forward commitment step.  
The catalytic details of PDH and KGDH are as follows (Figures 2 and 3). Each complex 
contains enzymatic activities conventionally referred to as E1, E2, and E3. E1 catalyzes 
oxidative decarboxylation (of pyruvate or alpha-ketoglutarate, respectively) using a 
thiamine pyrophosphate co-enzyme. The activated acyl unit created by this process is 
transferred to sulfhydryl groups of a lipoic acid (lipoate) residue of an E2 subunit. E2 lipoate 
is in the form of lipoamide, in which the carboxylic acid moiety of lipoate is joined in amide 
linkage to epsilon amino group of an E2 active site lysine. The two sulfurs on the lipoate 
moiety (Figures 3) exist in a disulfide configuration which is reduced and acylated 
(thioesters) to produce activated acetate or succinate residues. The E2 subunit further 
catalyzes the transfer of the lipoate-activated acyl residue to CoA leaving dihydro-
lipoamide. Finally, the E3 subunit catalyzes the transfer of the reducing potential in the 
dihydro-lipoamide residues of E2 to NAD+ (through enzyme disulfide to FAD to NAD 
steps) [7,8] to generate NADH for transfer of the reducing potential to the electron transport 
complex and regenerating oxidized lipoate (Figure 2).  
Both PDH and KGDH are very large complexes containing multiple copies of each of these 
three key enzymatic activities (Figure 3). For example, mammalian PDH consists of 60 
copies of the E2 subunit (48 of E2 itself and 12 of the E2 homolog called the E3 binding 
protein, E3BP; Figure 3) [9].  
This organization allows efficient channeling of the products of the intermediate reactions 
[10]. Flux through these complexes is subject to extensive regulation as expected from 
their central role in governing carbon flow in the face of variable supply and demand. The 
end products of PDH and KGDH activity, NADH and acyl-CoA, inhibit complex activity 
directly, apparently by binding to the E2 and E3 active sites, respectively [11,12]. 
However, PDH is much more extensively regulated through its associated kinases and 
phosphatases [13].  
The four PDKs that regulate the mammalian PDH complex are a novel class of kinases 
apparently unrelated to the large families of serine-threonine and tyrosine kinases so 
prominent in other mammalian regulatory processes as reviewed in [7,8]. These kinases are 
named on the basis of their order of discovery, PDKs1-4. Though the PDKs represent a 
related family of kinases, the sequence divergence between the four different isoforms (61-
69%) is consistent with their significantly divergent regulatory behavior [14,15]. Moreover, 
PDK isoform function is apparently ancient and essential as the corresponding isoforms in 
rodents and humans are at least 94% conserved as reviewed in [15]. 
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Figure 2. The catalytic cycle of the pyruvate dehydrogenase (PDH) complex. This cycle begins with the 
oxidative decarboxylation of pyruvate catalyzed by the E1 subunit, generating carbon dioxide and an 
activated two carbon unit (hydroethyl thiamine pyrophosphate, HE-TPP) as illustrated at the 10 o’clock 
position. E1 then catalyzes the transfer of this two carbon unit to one of the lipoate residues of the E2 
subunits, creating acyl-lipoamide as illustrated at the 12 o’clock position. The E2 catalytic activity 
transfers this two carbon unit to CoA, creating acetyl-CoA and dihydro-lipoamide as illustrated at the 4 
o’clock position. Finally, E3 catalyzes the transfer of the dihydro-lipoamide to NADH (through protein 
sulfhydryl and FAD intermediates) to recreate the oxidize form, lipoamide, as illustrated at the 8 o’clock 
position. Both the E2 catalyzed transfer of the lipoamide acyl group to CoA and the E3 catalyzed 
transfer of dihydro-lipoamide reducing potential to NADH are highly reversible reactions. Figure 
redrawn from several sources, including [8]. 
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Figure 3. Functional organization of the pyruvate dehydrogenase (PDH) complex in mammals. This 
complex catalyzes the oxidative decarboxylation of pyruvate to yield acetyl-CoA to feed carbohydrate 
carbon into the TCA cycle and to capture reducing potential in NADH for transfer to the electron 
transport complex (ETC) to support ATP synthesis during step down transfer to molecular oxygen 
(Figure 2). The mammalian PDH complex is built around a core consisting of the inner domains of ca. 
48 copies of the catalytically active E2 protein and 12 copies of the catalytically inactive E2 homolog, 
E3BP, The E1 subunit binds to E2 and the E3 subunit binds to E3BP. Both E2 and E3BP contain lipoate 
residues joined in amide linkage to the epsilon amino groups of specific lysine residues in the lipoyl 
domains (L1-L3). The lipoamide residues on the two lipoyl domains of E2 and the single domain of 
E3BP are acylated, reduced and re-oxidized during the PDH catalytic cycle (Figure 2). The zig-zag lines 
indicate highly flexible proline-rich domains allowing the E2 subunits high mobility throughout the 
complex and, perhaps, beyond. The regulatory kinases (PDKs) control PDH activity by phosphorylating 
(inactivating) the E1 subunit of the complex. Their activity is antagonized by two phosphatases (PDPs). 
The status of E2 lipoate residues strongly modulates the activity of the PDKs with acylation/reduction 
stimulating PDK activity. Figure redrawn from several sources, including [7].The PDKs normally 
function as dimers [see, for example 16,17]. Of particular potential importance is the observation that at 
least two of the PDK isoforms (PDK1 & 2) readily form heterodimers [18].  This raises the possibility 
that there might be as many as 10 different PDK isoforms (four homodimers and six heterodimers). In 
view of the substantial changes in PDK levels associated with malignancy (below), this potential 
complexity may be very important and is worthy of more investigation. 
The PDKs regulate PDH complex activity by responding to diverse allosteric modulators. 
High ratios of acetyl-CoA to CoASH and NADH to NAD+ represent signals of saturation of 
mitochondrial demand. Elevations of these ratios are strong allosteric activators of PDKs, 
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shutting down PDH activity in response to demand saturation [19, 20, 21]. Though 
saturation of mitochondrial demand is most often produced in response to high fat or 
carbohydrate intake in healthy animals, as reviewed in [8], the altered metabolism of tumor 
cells also creates a very new metabolic environment wherein these regulatory processes may 
be entrained for different purposes (below). 
PDKs are also subject to allosteric regulation by pyruvate [22] . Elevated pyruvate levels 
interact synergistically with ADP to inhibit PDK activity (activating PDH). This PDK 
inhibition apparently results from the binding of pyruvate to PDK-ADP inhibiting exchange 
for ATP and, thus, phosphorylation. Dichloroacetate (DCA) is a pyruvate analog and acts 
very similarly to pyruvate in this allosteric modulation of PDK activity [22] DCA was 
subsequently investigated as an anticancer drug (below) on the basis of this observation. 
The final relevant feature of PDK regulation is the response of these regulatory kinases to 
the lipoyl domains of the E2 subunits of PDH [7, 8, 23]. PDK1-3 bind strongly to the L2 
lipoate domain of E2 and more weakly to the E2 L1 lipoyl domain (Figure 3). PDK4 binds to 
the L1 E2 domain and to the sole lipoyl domain of E3BP (Figure 3). This lipoyl domain 
binding requires the lipoamide component of the domain. Moreover, the well characterized 
binding of PDK3 to the E2 L2 domain defines the binding site in detail including the amino 
acids interacting with the lipoamide residue [16]. These residues are highly conserved in 
PDK structure [17] indicating that this binding mode is likely universal to the PDKs. This 
binding of PDKs to E2 lipoyl domains juxtaposes them to their E1 target (associated with the 
E2 subunit binding domain; Figure 3), producing a large increase in the kinase reaction rate. 
PDK dimers apparently interact simultaneously with two lipoyl domains, producing very 
high binding affinity to the PDH complex and supporting hand-over-hand migration of the 
PDKs through the complex [24]. 
Most importantly for our purposes here, the reduction and acylation state of the E2 lipoates 
strongly modulates associated PDK activity [25, 26]. Specifically, acylation and reduction of 
lipoate enhances PDK2 activity [7,8, 27]. Moreover, acetyl-CoA and NADH can be used as 
substrates to run elements of the PDH reaction (above) in reverse, thereby creating reduced 
and/or acylated lipoate residues in response to elevation in the levels of acetyl-CoA and 
NADH in the mitochondrial matrix [25,26]. In other words, the lipoate residues of PDH 
represent a real-time census of these crucial features of the energy status of the 
mitochondrial matrix. 
Several additional details of lipoate regulation of PDH and KGDH are also relevant for this 
discussion. The lipoates in PDH and KGDH comprise a dense cloud of highly mobile 
residues [28], potentially interacting with crucial regulatory functions. This condition results 
from several features of the structure of these complexes. PDH illustrates the crucial issues. 
Each of the ca. 48 E2 subunits contains 2 lipoate (lipoamide) residues and each of the 12 
E3BP proteins contains 1 such residue, for a total of 108 lipoate residues in each complex. 
The regulatory kinases (PDKs-1-4) interact with these lipoate residues embedded in the 
lipoyl domains (Figure 3). Moreover, these lipoyl domains not only have the boom-like 
structure resulting from their connection to lysine epsilon amino groups in the E3 lipoyl 
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binding domains, but also each of these domains is separated by highly flexible 
(alanine/proline-rich) linker domain.  
These details will be important to us below in considering the possible mechanisms of action 
to pursue in developing new drugs based on lipoate structure. Specifically, each PDK can 
potentially interact simultaneously with two lipoate residues, as well as rapidly migrate 
between residues. This creates an environment in which PDKs may effectively sample the 
lipoate cloud, regulating their activity in response to what is effectively a measurement of 
the aggregate cloud status, especially the acylation/redox status of lipoate as determined by 
both forward flux through the complex and by backward charging of lipoate from NADH 
and acetyl-CoA products (above).  
Such a sampling procedure would yield especially robust assessment of enzyme saturation 
and, thus, allow PDK control of PDH to be more reliably connected to the global 
mitochondrial energy status. In vitro studies demonstrate that free lipoate can interact with 
the PDH (and KGDH) complexes [29]. Thus, we anticipate that exogenous lipoate analogs 
might be effective in modulating the activity of PDK bound to the PDH complex (below). 
3. Clinical implications of the reconfiguration of metabolism in cancer 
cells 
The hypothesis that metabolism may be altered in important ways in cancer is longstanding 
[30]. However, our understanding of cancer metabolism and its relationship to malignancy 
and clinical outcome has only recently begun to receive extensive attention. Though our 
knowledge about cancer metabolism remains quite incomplete, some important global 
insights have emerged. 
First, fluxes of both glucose and glutamine, two major carbon sources, are substantially up-
regulated in many tumors as reviewed in [31-36]. More specifically, mutational changes 
altering signaling through the Akt pathway enhance glucose uptake and glycolytic 
metabolism [37]. Likewise, alterations of Myc expression substantially up-regulate 
glutamine utilization [3, 38, 39]. 
Second, evidence from multiple perspectives supports the view that one of the major 
functions of these tumor-specific changes is the redirection of metabolism toward provision 
of increased levels of anabolic substrates. For example, large fractions of glucose carbon are 
diverted into the pentose phosphate pathway in support of nucleotide synthesis and into 
amino acid biosynthesis. Likewise, a large portion of glutamine carbon is siphoned off of the 
TCA cycle as citrate to support lipid biosynthesis (including fatty acids and sterols) (Figure 
1). We can call this the anabolic shift in tumor cells. 
The therapeutic implications of the alterations in cancer metabolism depend heavily on how 
unique these changes are to tumor cells. There is good evidence that some elements of the 
anabolic shift are not unique to tumors cells, but may also be shared with rapidly dividing 
normal cells. For example, activated lymphocytes show some of these same metabolic 
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properties [40]. However, there is also reason to suspect that other features of the cancer cell 
version of the anabolic shift will not be shared with most normal, rapidly dividing cells. In 
particular, the poor vascularization of solid tumors reflects an environment rather different 
than rapidly dividing normal cells typically experience [41, 42]. Tumor cells are likely to 
have additional metabolic adaptations to this extreme environment. 
Of course, the existence of such metabolic adaptations to the extreme tumor 
microenvironment may still not be helpful therapeutically if these adaptations are 
idiosyncratic to each individual case of cancer. Fortunately, there is both empirical and 
theoretical reason to believe that these special adaptations will, in fact, be generally 
consistent and predictable, as we now discuss. It has long been recognized that solid tumors 
bear a striking resemblance to healing wounds [43-45]. Specifically, solid tumors resemble 
wounds that continue the early steps in wound healing, but never resolve as normal wound 
healing does. Thus, it is plausible to speculate that metabolic modifications in tumor cells 
usually or always involve the pathological, uncontrolled activation of regulatory pathways 
normally accommodating cells to the rigors of the wound environment. On this working 
hypothesis, tumor metabolism is expected to have features not shared with normal cells 
(except potentially in healing wounds) and to be potentially universal to most or all cancers. 
The possibility that tumor metabolism might have unique features is particularly important 
therapeutically. The dramatic increase in our knowledge about the genetic changes in cancer 
and our experience with genetically targeted therapies has produced some sobering 
potential insights as illustrated by the following examples. Specifically, in many or even 
most cancers, the “driver” mutations may represent loss-of-function in tumor suppressors 
rather than gain-of-function mutations [46-48]. Moreover, the fraction of tumor-producing 
changes that are epigenetic may be high. All of these features mean that targeting specific 
oncogene-targeted products, such as small molecules like gleevec, may be viable in only a 
minority of tumors [49]. 
Finally, the levels of redundancy in the regulatory circuits mutated in cancers mean that 
targeting an individual gain-of-function driver, even when it is possible, may be 
incompletely successful and subject to evolved resistance.  
The upshot of these genetic considerations is that chemotherapy might be better focused on 
properties of the transformed state rather than on the genetic drivers producing that state. 
Moreover, non-redundant, indispensable properties of the transformed state are expected to 
represent the most propitious of such targets. Cancer metabolism may represent an 
environment in which such desirable targets exist. Below we will develop the argument that 
the dehydrogenases at key control points in metabolism are especially attractive candidates 
for such targets.  
4. Modification of PDH regulation is vital to malignant transformation 
If cancer metabolism is to be a therapeutic target it is vital to identify likely targets for 
intervention. In this section we will review some of the evidence that the PDKs regulating 
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PDH activity are excellent potential candidates for such targets. Later we will return to the 
question of whether the other major dehydrogenase entry point for mitochondrial 
metabolism, KGDH, might also be an attractive therapeutic target. 
PDKs have long been recognized as key regulators of PDH function (above). Moreover, in 
view of the central role of modification of carbohydrate metabolism in cancer (above), 
alteration of PDK regulation in malignancy is likely. Initially, analysis of clinical samples 
demonstrated that up-regulation of PDK levels was a frequent correlate of advanced 
malignancy [50] a pattern that has persisted in subsequent studies [51]. 
These and other observations stimulated systematic detailed study to great effect. Kim, et 
al., [52] and Papandreou, et al. [53] demonstrated that HIF-1, a global regulator of the 
hypoxic response, up-regulated PDK1, with the expected effect of down-regulating carbon 
flow through PDH. Moreover, PDK up-regulation correlated with increased resistance to 
programmed cell death, a hallmark of cancer as reviewed in [54]. In view of the consistent 
hypoxia in solid tumors as reviewed in [41, 42] and the frequent activation of HIF1 in 
tumors as reviewed in [55] these observations suggested that PDK up-regulation might be a 
central element of the cancer metabolic reconfiguration.  
The next challenge was to ask if more direct evidence for the importance of PDK up-
regulation in cancer metabolism could be found. Was PDK up-regulation required for 
malignancy or marginal, epiphenomenal?  Several observations argue strongly that PDK up-
regulation is essential to the malignant phenotype. 
First, McFate, et al. [56] demonstrated that PDK1 up-regulation was essential for the 
malignant phenotype in head and neck squamous cell carcinoma cells (HNSC). Specifically, 
PDK1 expression contributed to induction of limited flux of carbon through mitochondrial 
metabolism and PKD1 over-expression further reduced this flux (as measured by glucose 
consumption and diversion of carbohydrate carbon to lactate formation). Confirming this 
relationship, PKD1 knockdown increased TCA processing of carbohydrate carbon. PDK1 
knockdown reduced several indicators of malignant potential, including ability to resist cell 
death under hypoxia or to form colonies in soft agar in culture. Most importantly, PDK1 
knockdown dramatically, reduced the rate of tumor growth in xenograft models.  
Earlier work from this group indicated that accumulation of glycolytic intermediates might, 
itself, be sufficient to up-regulate HIF1 [57]. Thus, McFate [56] proposed a positive feedback 
loop central to the malignant state wherein PDK1 up-regulation by HIF1 enhanced 
production of glycolytic intermediates (by blocking pyruvate consumption) further up-
regulating HIF1 and so on. 
Second, Lu, et al. [58] found a similar role for HIF1-dependent up-regulation of PDK3 in 
malignant metabolic state. In this case also, reduction in mitochondrial carbohydrate 
metabolism with the corresponding up-regulation of oxygen-independent cytosolic 
glycolysis was driven by elevated PDK3 expression. Of particular importance here, the 
resistance of tumor cells to killing by chemotherapeutic agents paclitaxel and cisplatin was 
strongly improved by PDK3 up-regulation, while PDK3 knockdown sensitized to these 
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agents. Finally, Lu, et al. [58] observed that both PDK1 and PDK3 collaborated to produce 
this drug resistance. 
Collectively, these results clearly indicate that PDK regulation of PDH activity is central to 
the malignant phenotype. Moreover, there is apparently no metabolic bypass of the 
requirement for properly managed mitochondrial metabolism. Mitochondria are not turned 
off in hypoxic tumor cells. Rather, they are redeployed to provide the limited carbon traffic 
they can sustain to the provision of anabolic intermediates (above). There appears to be no 
other way to provide some of these biosynthetic resources (citrate for lipid biosynthesis, for 
example). Further, mitochondria are central controllers of Ca++ signaling [see 59 and 
references therein] and of cell death control as reviewed in [60,61]. Thus, their continued 
properly controlled function is likely to be essential to cancer cell homeostasis and survival. 
These results and considerations are consistent with the hypothesis that this re-regulation of 
PDH cannot be dispensed with. Without this metabolic pattern cancer cells are likely to be 
unable to survive and prosper in the hypoxic environment crucial to malignant progression. 
Thus, PDK re-regulation is a candidate for the kind of essential, non-redundant therapeutic 
target needed if we are to have fundamentally new clinical options. We will argue below 
that this target can be therapeutically exploited in several different ways. 
Before turning to assessment of how we might attack this potential target it is important to 
emphasize a particular implication of PDK re-regulation in cancer cells. Because of the 
possibility of PDK heterodimer formation (above), tumor-specific quantitative changes in 
individual PDK expression may be substantially amplified in their regulatory effects. For 
example, if PDK1 and PDK3 were both up-regulated 10 fold in the in vivo tumor 
environment, this could represent a 100-fold increase in the levels of the hypothetical 
PDK1/PDK3 heterodimer. Such very large effects might represent targets that are essentially 
qualitatively unique to tumor cells. 
5. DCA, attempting to reverse tumor-specific PDK repression of PDH 
activity 
Dichloroacetate (DCA) is a small molecule with a long history of clinical use for treatment of 
elevated serum lactate levels in some inherited metabolic conditions [62]. Moreover, DCA is 
well characterized as being a non-metabolizable pyruvate analog that can strongly inhibit 
PDK function [17,22, 63] .Thus, DCA is a candidate to reverse PDK repression of PDH 
important to cancer cell tumorigenicity (above). 
These considerations influenced Bonnet [1] to investigate DCA’s potential anti-cancer 
effects. These authors observed that DCA treatment could reverse the mitochondrial 
membrane hyper-polarization characteristic of tumor cells without noticeable effect on the 
lower level of polarization in normal cells. Further, DCA substantially increased glucose 
oxidation while decreasing fatty acid oxidation in A549 tumors cells [1]. These and other 
effects correlate with DCA inhibition of cancer cell growth and induction of a modest 
increase in the rate of cancer cell apoptosis. Finally and most importantly, DCA very 
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significantly inhibits tumor growth in mouse xenograft models. Specifically, DCA 
administered ad libitum in drinking water at 75mg/l produced both inhibition of xenograft 
tumor growth and modest, but significant reduction in tumor volume in larger tumors. 
Subsequent reports from other groups corroborate these preclinical findings [64, 65]. 
The clinical follow up on these preclinical results has been generally weak. This largely 
results from economic factors. DCA is a cheap, generic drug and no corporate actors have an 
incentive to develop the agent. To date clinical data consist of several anecdotal case reports 
[66,67] suggesting possible efficacy, including in a poorly differentiated metastatic 
carcinoma. In addition, in view of its low cost and wide availability, DCA is being 
prescribed off-label or self- administered. Anecdotal reports of efficacy from this use group 
can be found in patient/physician webshops (see, for example, www.thedcasite.com). It will 
be of considerable interest to see if sufficient evidence can be accumulated to assess the 
clinical potential of this agent.  
An apparently common side effect of DCA use is peripheral neuropathy. Though this is 
generally limited and reversible, this may not always be the case. A patient report describes 
relatively severe encephalopathy probably induced by DCA doses within the range 
currently being experimented with by patients and their physicians [68]. These problems 
emphasize the importance for individual patients of using DCA only under professional 
medical supervision.  
Finally, a series of small molecule PDK inhibitors have been developed, initially for the 
treatment of diabetes as reviewed in [8]. These compounds are far more potent than DCA on 
a mole basis and it will be of interest to see if they have significant anti-cancer activity. To 
date, no clinical trial data are available on any possible anti-cancer activities of these agents. 
Moreover, the design strategy for these compounds renders them relatively selective for 
individual PDK homodimers. We do not currently know which homo- or heterodimer(s) 
might be the most propitious anti-cancer target(s) for this class of agents. 
6. Thioctoid lipoate analogs exaggerate cancer-specific, PDK-mediated 
repression of PDH to shut down tumor cell mitochondria and induce cell 
death 
The PDH complex includes a dense cloud of lipoate residues making up the functional 
catalytic co-factor domain of the E2 activity (above). Acyl groups and reducing potential can 
be back-transferred to this lipoate cloud from the surrounding mitochondrial matrix pool as 
well as being generated by the conventional PDH forward reaction (above). Moreover, these 
acyl groups and reducing potential can apparently be rapidly shuttled between these 
residues before ultimately being transferred to CoA and NAD+[28]. Finally, the 
oxidation/acylation state of the elements of the lipoate cloud strongly effect the activity of 
the PDK regulatory kinases, with acylation/reduction stimulating PDK activity (above). 
Thus, each PDK homo- or heterodimer docked at any point on the PDH complex is 
apparently continuously exposed to the result of an ongoing, real-time poll of the 
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mitochondrial matrix energy status. Further, these PDKs are then able to act rapidly on all 
their E1 targets in the PDH complex in response to these polling results as a result of the 
combination of the highly flexible linkers surrounding the lipoyl domains to which they are 
bound (Figure 3) and their ability to move hand-over-hand through the complex.  
In vitro studies demonstrate that free lipoate and lipoate-containing lipoyl domain 
fragments can interact productively with the intact PDH complex (above). This suggests that 
lipoate analogs might be able to perturb PDH regulation in vivo. Moreover, this perturbation 
might show strong selectivity for tumor cells in view of the substantial reconfiguration of 
PDK regulation in cancer (above). Based on the original PDH regulatory biochemistry and 
the presumption, subsequently confirmed (above), that PDH regulation was likely to be 
substantially altered in tumor cells, we began a systematic study of lipoate analogs as anti-
cancer agents in the late 1990s (Patent # 6331559, filed 1999). The concept was that 
appropriately designed lipoate analogs might mimic the effects of specific intermediate 
states of lipoate (Figures 3 and 4) on PDK function and, thereby, misinform the PDH 
regulatory machinery in ways that were selectively toxic to tumor cells. 
These studies initially demonstrated that lipoate analogs, designated thioctoids, had strong 
anti-cancer activity in cell culture [2; our unpublished results]. Many of our initial analyses 
were carried out using our current lead clinical investigational compound, CPI-613 (Figure 
4). Indeed, these agents induce cell death in cancer cells extremely efficiently, with all cells 
dying within 24-48 hours by a mixture of apoptosis and necrosis-like mechanisms. This is in 
contrast to DCA which typically induces cell death in only a small fraction of tumor cells in 
culture [1; our unpublished results]. Each of the many human tumor cell lines we have 
examined is comparably sensitive to thioctoids, with tumor genotype at oncogenes and 
multidrug resistance loci having little or no effect on response [2]. 
Though the precise biochemical mechanism of action of thioctoids remains to be established, 
the in vivo behavior of these compounds demonstrates that they modulate PDK regulation 
of PDH [2; our unpublished results]. Moreover, these tumor effects are diametrically 
opposite to the effects of DCA and of other small molecule PDK inhibitors. Specifically, 
DCA induces de-phosphorylation of PDH E1 in vivo [55] while thioctoids induce hyper-
phosphorylation in vivo [2; our unpublished results]. This thioctoid-induced PDH hyper-
phosphorylation is selective for tumor cells and correlates with inactivation of PDH activity 
as assessed by analysis of the oxidative flux of pyruvate carbon through the complex. 
Coincident with this inhibition of PDH activity, thioctoids induce rapid shut down of 
mitochondrial ATP synthesis, typically reducing mitochondrial ATP production from 
pyruvate and glutamine carbon sources to less that 10% of controls within 15-30 minutes [2]. 
Finally, the capacity of CPI-613 to kill tumor cells is significantly attenuated in cell culture 
systems by RNAi knockdown of regulatory PDKs, supporting a role for PDKs in the 
response to these agents. 
Collectively, these results indicate that thioctoid lipoate analogs kill tumor cells by 
addressing tumor-specific PDK regulation of PDH. Moreover, the consequence of these 
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effects is apparently to exploit tumor-specific PDH regulation, in part or entirely, to shut 
down tumor mitochondrial function. As continued mitochondrial function is required for 
the survival of tumor cells, even in the hypoxic solid tumor environment (above), these 
effects are expected to engender the observed response, rapid commitment to and execution 
of mitochondrially controlled cell death pathways. 
 
Figure 4. Structure of thioctoid CPI-613 compared to biogenic lipoates. The structure of the thioctoid 
CPI-613 is shown at bottom. This molecule is a non-redox active analog of lipoate designed to have 
some resemblance to the acylated form of lipoate as it occurs in the normal catalytic cycle of PDH 
(Figure 2). The corresponding biogenic lipoate intermediates in the PDH catalytic cycle are 
illustrated at top. 
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These properties suggested that thioctoids might be promising anti-cancer agents. This 
possibility is further supported by their behavior in human tumor xenograft mouse models. 
Specifically, CPI-613 produces strong tumor growth inhibition in several tumor types. For 
example, the growth of BxPC-3 human pancreatic tumor xenografts implanted 
subcutaneously on posterior flanks is largely or entirely suppressed by intraperitoneal 
dosing with CPI-613 at 25-75mg/kg. Moreover, ca. 40% of these animals survive for more 
than 9 months (termination of study) without regrowth of tumors after an initial three week 
treatment regime. [A large fraction of the 60% mortality in this study is attributable to 
normal attrition in these genetically immunocompromised nude mice. Thus, cancer-free 
post-treatment survival in these animals is apparently substantially higher than 40%.] 
Titration studies demonstrate that CPI-613 produces very substantial tumor growth 
inhibition in xenograft model systems at doses (0.1-1mg/kg) very substantially lower than 
the maximum tolerated dose (ca. 100mg/kg)[2; our unpublished results]. This indicates a 
very high possible therapeutic index. Large-animal toxicology studies further corroborate 
the very low toxicity of CPI-613 [69]. Moreover, drug metabolism studies indicate that CPI-
613 breakdown products are unlikely to pose a barrier to clinical development [70].  
Based on this favorable mechanistic and pre-clinical animal data, Phase I/II clinical trials are 
currently underway at several locations (see comments at http://clinicaltrials.gov/ 
ct2/show/NCT01520805). These studies indicate that adverse events of CPI-613 in humans 
are low and mostly mild (well tolerated to at least 3,000mg/m2, when infused over one hour) 
and suggest efficacy against several advanced cancers, including refractory/relapsed AML, 
in several patients [71-73]. It will be of interest to continue to pursue the clinical 
investigation of these investigational drugs. 
7. The central role of lipoate as a metabolic regulatory signal, other 
potential thioctoid tumor targets 
In view of the capacity of thioctoids to attack tumor cell PDH it may be of value to consider 
the potential of these agents to address tumor metabolism more generally. Indeed, the 
properties of lipoate suggest that it may act as a global mitochondrial regulatory signaling 
molecule, possibly addressing the entire flow of carbon through this compartment. On this 
view, lipoate analogs may address multiple regulatory pathways, some or all altered in 
tumor cells analogously to the well-understood PDH case. 
Specifically, two other enzyme complexes are recognizably homologous to PDH and 
catalyze analogous reactions. One of these is the branched chain oxoacid dehydrogenase 
complex (BCDH) as reviewed in [74]. The other is the KGDH complex (above). BCDH 
governs the entry of carbon from a series of amino acids into the TCA cycle. KGDH governs 
the entry of glutamine-derived carbon (Figure 1). Together with PDH control of 
carbohydrate derived carbon, these three enzymes directly control initial access of all carbon 
to the TCA cycle, except for that derived from fatty acids. Moreover, even fatty acid-derived 
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carbon flow is implicitly governed by lipoate-dependent dehydrogenases because no fatty 
acid carbon can be oxidatively released without first passing through the KGDH complex 
[6]. Thus, all carbon flow through mitochondria is ultimately controlled by lipoate-
containing enzymes. 
The role of lipoate residues in controlling PDH function and the unique capacity of these 
residues to poll and reflect the mitochondrial energy status strongly suggests that lipoate 
residues will play a role in regulating BCDH and KGDH function. While this possibility 
remains to be investigated, it is noteworthy that the BCDH complex is regulated by kinases 
homologous to PDKs. It is plausible that these regulatory kinases are also responsive to 
lipoate redox/acylation state. Moreover, in view of the rather dramatic reprogramming of 
tumor mitochondrial metabolism, it is also plausible that BCDH regulatory kinases may be 
reprogramed in malignancy.  
KGDH is apparently not regulated by PDK-like kinases and the details of its metabolic 
regulation remain to be investigated. However, the complex shows strong allosteric 
regulation by end products, consistent with important regulatory objectives [75, 76]. Thus, it 
is likely that KGDH lipoates also participate in this regulation in some way that largely 
remains to be determined. 
As reviewed in section 3 above,  the lipoate residues of PDH, BCDH and KGDH exist as a 
cloud polling crucial features of the mitochondrial energy state, including the aggregate 
levels of free reducing potential (NADH) and of their respective acyl-CoA products. 
Moreover, these details of the mitochondrial energy state are likely to be among the state 
variables most informative about the moment-to-moment metabolic needs of the 
mitochondrion. Further, these regulatory goals of mitochondria are so substantially altered 
in tumor cells that we anticipate that all these potential lipoate-sensitive regulatory targets 
might be substantially altered in tumor cells, as they clearly are in the PDH case. Finally, the 
long boom-like structure of the enzyme linked lipoamide moieties (Figures 2) and their 
attachment to highly mobile E2 enzyme subdomains (Figure 3) raises an additional 
important regulatory possibility. It is conceivable that these actively polling lipoate residues 
are not merely reporting their results to their individual complexes but also to other 
mitochondrial consumers of regulatory information.  
Collectively, these considerations suggest that thioctoid lipoate analogs may achieve their 
dramatic inhibition of tumor cell mitochondrial metabolism by addressing multiple, 
essential metabolic regulatory processes in a tumor-specific fashion. The promising pre-
clinical and early clinical properties of thioctoid CPI-613 indicate that it will be of interest to 
explore this possibility in detail going forward. 
8. Conclusions 
The central role of lipoate-dependent dehydrogenases in governing carbon flow through 
mammalian mitochondria is reflected in their extensive regulation. Moreover, both 
empirical evidence and theoretical considerations indicate that the regulation of these 
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complexes is strongly controlled by the dynamic status of their lipoate residues, reflecting a 
moment-to-moment polling of the mitochondrial matrix. Finally, evidence and theory also 
indicate that some or most of these lipoate-dependent regulatory processes are very 
significantly altered in support of the substantial repurposing of tumor cell mitochondrial 
metabolism relative to its normal cell condition. 
Collectively, these results indicate that the regulatory reprogramming of these 
dehydrogenases may represent a target-rich environment for developing new anti-tumor 
drugs that have the crucial properties that may be required to impart new efficacy to cancer 
chemotherapy – targets that are both essential to the malignant condition and non-
redundant in their function. The preclinical and early clinical properties of agents directed at 
these targets support the possibility of useful promise in this therapeutic domain. 
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